MedTrace Logo

Autoimmune Cytopenia Elimination by Chimeric Antigen Receptor T-cell Therapy

NCT07790575 · Status: NOT_YET_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2026-08-27

No results posted yet for this study

Summary

This is a phase 1 study to evaluate the safety and tolerability of AZD0120 in patients with relapsed or refractory immune mediated cytopenia (primary chronic Immune Thrombocytopenia (ITP) or autoimmune hemolytic anemia (wAIHA)).

Conditions

  • Cytopenia

Interventions

DRUG

AZD0120

One time administration on Day 0.

DRUG

Bendamustin

Participants will be given bendamustin for 2 days (study Day -5 and Day -4) followed by 3 days of rest.

Sponsors & Collaborators

  • Saurabh Dahiya

    lead OTHER

Principal Investigators

  • Saurabh Dahiya, MD · Stanford University

Study Design

Allocation
NON_RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-09-30
Primary Completion
2041-07-31
Completion
2041-07-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07790575 on ClinicalTrials.gov